Form 4: Enliven Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Benjamin Hohl, CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc., sold 6,018 shares of common stock on July 17, 2026.
Summary
- Option exercise/conversion: acquired 1,072 Common Stock at $2.48 ($2,659) on July 17, 2026; holds 52,072 after (Direct).
- Open-market sale: disposed of 324 Common Stock at $49.97 ($16,191) on July 17, 2026; holds 51,748 after (Direct).
- Open-market sale: disposed of 369 Common Stock at $51.48 ($18,997) on July 17, 2026; holds 51,379 after (Direct).
- Open-market sale: disposed of 2,564 Common Stock at $52.32 ($134,143) on July 17, 2026; holds 48,815 after (Direct).
- Open-market sale: disposed of 2,638 Common Stock at $53.38 ($140,823) on July 17, 2026; holds 46,177 after (Direct).
- Open-market sale: disposed of 123 Common Stock at $53.87 ($6,626) on July 17, 2026; holds 46,054 after (Direct).
- Option exercise/conversion: disposed of 1,072 Stock Option (right to buy) on July 17, 2026; holds 84,966 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $316,780 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Benjamin Hohl — Officer (CHIEF FINANCIAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Option exercise/conversion | Common Stock | 1,072 | $2 | $2.7K | 52,072 |
| 2026-07-17 | Open-market sale | Common Stock | 324 | $50 | $16.2K | 51,748 |
| 2026-07-17 | Open-market sale | Common Stock | 369 | $51 | $19.0K | 51,379 |
| 2026-07-17 | Open-market sale | Common Stock | 2,564 | $52 | $134.1K | 48,815 |
| 2026-07-17 | Open-market sale | Common Stock | 2,638 | $53 | $140.8K | 46,177 |
| 2026-07-17 | Open-market sale | Common Stock | 123 | $54 | $6.6K | 46,054 |
| 2026-07-17 | Option exercise/conversion | Stock Option (right to buy) | 1,072 | — | — | 84,966 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Option exercise/conversion (1,072 shares) |
| 2026-07-17 | Open-market sale (324 shares) |
| 2026-07-17 | Open-market sale (369 shares) |
| 2026-07-17 | Open-market sale (2,564 shares) |
| 2026-07-17 | Open-market sale (2,638 shares) |
| 2026-07-17 | Open-market sale (123 shares) |
| 2026-07-17 | Option exercise/conversion (1,072 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, Benjamin Hohl
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.